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ABSTRACT
Recently, the Cancer Genome Atlas (TCGA) Research Network and Asian 
Cancer Research Group provided a new classification of gastric cancer (GC) to aid 
the development of biomarkers for targeted therapy and predict prognosis. We 
studied associations between genetically aberrant profiles of cancer-related genes, 
environmental factors, and histopathological features in 107 paired gastric tumor-
non-tumor tissue GC samples. 6.5% of our GC cases were classified as the EBV 
subtype, 17.8% as the MSI subtype, 43.0% as the CIN subtype, and 32.7% as the 
GS subtype. The distribution of four GC subgroups based on the TCGA and our dataset 
were similar. The MSI subtype showed a hyper-mutated status and the best prognosis 
among molecular subtype. However, molecular classification based on the four GC 
subtypes showed no significant survival differences in terms of overall survival (p= 
0.548) or relapse-free survival (RFS, p=0.518). The P619fs*43 in ZBTB20 was limited 
to MSI group (n= 5/19, 26.3%), showing similar trends observed in TCGA dataset.
Genetic alterations of the RTK/RAS/MAPK and PI3K/AKT/mTOR pathways were 
detected in 34.6% of GC cases (37 individual cases). We also found two cases with 
likely pathogenic variants (NM_004360.4: c. 2494 G>A, p.V832M) in the CDH1 gene.
Here, we classified molecular subtypes of GC according to the TCGA system and 
provide a critical starting point for the design of more appropriate clinical trials based 
on a comprehensive analysis of genetic alterations in Korean GC patients.
INTRODUCTION
Gastric cancer (GC) is ranked fifth for cancer 
incidence and second for cancer deaths, and one in 36 men 
and 1 in 84 women develop stomach cancer before age 79 
[1]. The histologic classification of gastric carcinoma has 
been based on the Lauren [2] and 2010 WHO classification 
systems, which recognize four histological subtypes [3]. 
Neither the Lauren nor the WHO system is particularly 
clinically useful, as their prognostic and predictive 
capabilities cannot adequately guide patient management. 
Thus, new classifications are needed for GC to provide 
insights into pathogenesis and the identification of new 
biomarkers and novel treatment targets [4]. Recently, 
advances in technology and high-throughput analysis have 
improved our understanding of the genetic basis of GC. 
To provide a roadmap for patient stratification and trials 
of targeted therapies, the Cancer Genome Atlas (TCGA) 
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Research Network has characterized 295 primary gastric 
adenocarcinomas and proposed a new classification of four 
different tumor subtypes of Epstein-Barr virus (EBV)-
positive, microsatellite instability (MSI), genomically 
stable (GS), and chromosomal instability (CIN) subtypes. 
[5]. The Asian Cancer Research Group (ACRG) also 
provided a new classification for GC, identifying four 
subtypes: MSI, MSS/EMT, MSS/TP53 (+), and MSS/
TP53(–). One of the most important aspects of the ACRG 
classification is that it correlates the molecular subtypes 
with clinical prognosis [6].
Helicobacter pylori has been accepted as a causative 
organism in GC [7, 8], and EBV is also now regarded as 
a GC-causing infectious agent. The original type of EBV-
infected GC makes up 5-10% of all GC cases [9, 10]. The 
vast majority of GC arise sporadically, and an inherited 
component contributes to <3% of gastric cancers [11, 
12]. The GC is a heterogeneous disease characterized 
by epidemiologic and histopathologic differences across 
countries [7, 8, 13, 14]. Here, we investigated germline 
mutations in CDH1, MSH2, MLH1, TP53, APC, and 
STK11, which are associated with hereditary diffuse 
gastric cancer, hereditary nonpolyposis colon cancer, Li–
Fraumeni syndrome, familial adenomatous polyposis, and 
Peutz–Jeghers syndrome, respectively [11, 12, 15–19]. 
Furthermore, we studied associations between the genetic 
aberrant profiles of cancer-related genes, environmental 
factors (EBV and H. pylori), and histopathological features 
in Korean GC patients. We also classified molecular 
subtypes of Korea GC.
RESULTS
Clinical and pathological findings of 107 Korean 
GC patients
The male to female ratio was 2:1 with median 
patient age of 70 years (range, 32-90). The intestinal type, 
diffuse type, and mixed type by Lauren classification 
accounted for 54.2%, 26.2%, and 19.6%, respectively. In 
addition, for GC classified according to the 2010 WHO 
classification, the tubular type (64.5%) was observed with 
the highest frequency, while the poorly cohesive type and 
mixed type accounted for 13.1% and 15.0%, respectively. 
More than half of the tumors were located in the antrum or 
antrum body, while about 7.5% were located in the cardia 
and gastroesophageal junction. Fifty-two cases (48.6%) 
were in stages III-IV, and 66 (61.7%) were H.pylori-
positive. The clinicopathological findings of the 107 GC 
patients are summarized in Table 1.
Germline variation analysis of hereditary 
cancer-predisposing syndrome
A total of 30 germline variants were observed in 
TP53, STK11, ALK, APC, MSH2, MLH1, and CDH1 
(Table 2). Among these, 16 variants, 12 variants, and 2 
variants were classified as 'Benign or Likely Benign,' 
'VUS,' and 'Likely pathogenic,' respectively. Two cases 
had a likely pathogenic variant (p.V832M) in CDH1 gene.
Molecular profile of gastric cancer with a 43 
gene cancer panel
To identify driver genes [20] causally linked to 
tumorigenesis in Korea GCs, variants were extracted 
from targeted sequencing with a 43 gene cancer panel 
applied to 107 tumor and matched non-tumor tissues. After 
mutation calling and stringent filtrations, we identified 317 
single-nucleotide variants (SNVs) on coding sequences 
that included missense variations (n=164, 51.7%), trunc 
(nonsense and frameshift) variations (n= 110, 34.7%), in-
frame variations (n= 42, 13.2%), and splicing site variations 
(n=1, 0.3%) (Supplementary Table 2). Somatic variants 
detected in each gene for each sample were summarized in 
Supplementary Table 3. Among the 43 genes, we discovered 
39 genes that were mutated in one or more individual 
samples. Among the 107 samples, TP53 (38.3%), ARID1A 
(36.4%), CR1 (15.0%), APC (11.2%), BCOR (11.2%), CDH1 
(10.3%), CIC (9.3%), PIK3CA (9.3%), ERBB3 (8.4%), 
RHOA (8.4%), ERBB2 (7.5%), CCND1 (6.5%), FBXW7 
(6.5%), ALK (5.6%), KRAS (5.6%), and MTOR (5.6%) were 
identified (Supplementary Table 3). Somatic variants were 
detected in relatively low frequencies (less than 5%) on the 
CTNNB1, EGFR, HLA-B, MSH2, PGM5, ZBTB20, IRF2, 
KDR, LARP4B, MVK, BRAF, PTEN, ACVR1B, CBWD1, 
FGFR2, JAK2, MEDAG, MLH1, SMAD4, STK11, CD274, 
MDM2, and MYC genes in this study. We did not detect any 
somatic variants on the C16orf74, CCNE1, PDCD1LG2, or 
MET genes (Supplementary Table 3).
Among 317 somatic variants, 110 (34.7%) were 
recurrently detected in this study (Table 3). According 
to the results of somatic variants, p.Gln1334del/dup 
or p.Asp1850ThrfsTer33 in ARID1A, p.Arg2194Ter 
in CR1, p.Glu280del in CCND1, p.Leu15del in 
CDH1, p.Arg678Gln in ERBB2, p.Gly13Asp in KRAS, 
p.His1047Arg in PIK3CA, and p.Pro619LeufsTer43 in 
ZBTB20 were recurrently detected in more than four 
individual cases (Table 3). Twenty-two copy number 
variation (CNV)s were identified in the BCOR (n=1), 
CCND1 (n=2), CCNE1 (n=3), ERBB2 (n=5), FGFR2 
(n=1), KRAS (n=6), MYC (n=1), PIK3CA (n=1), PTEN 
(n=1), and JAK2 (n=1) (Figure 1).
Genetic alterations of the RTK/RAS/MAPK or/
and PI3K/AKT/mTOR pathways were detected in 34.6% 
of GC cases (37 individual cases) (Figure 2). Receptor 
tyrosine kinase (RTK) genomic alterations including 
ERBB2 (n=13), EGFR (n=5), FGFR2 (n=3) and KDR 
(n=4) were detected in 20.5% of GC cases (n=22). 
Thirteen samples (12.2% of GC) harbored ERBB2 
alterations, 8 contained somatic base substitutions and 5 
harbored amplifications, with these events being mutually 
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Table 1: Clinicopathological characteristics of patients with gastric cancer (n=107)
Characteristics Number
Age (year)
Median (range) 70 (32 ~ 90)
Sex
Female 36 (33.6%)
Male 71 (66.4%)
Lauren class
Diffuse 28 (26.2%)
Intestinal 58 (54.2%)
Mixed 21 (19.6%)
WHO class
Mucinous 3 (2.8%)
Tubular 69 (64.5%)
Poorly cohesive 14 (13.1%)
Mixed (Tubular_Poorly cohesive) 16 (15.0%)
Uncommon histologic variants 5 (4.7%)
pT stage
T1a/T1b 9 (8.4%)/15 (14.0%)
T2 11 (10.3%)
T3 38 (35.5%)
T4a/T4b 33 (30.8%)/1 (0.9%)
pN stage
N0/N1/N2/N3 40 (37.4%)/16 (15.0%)/20 (18.7%)/31 (29.0%)
M stage
M0/M1 102 (95.3%)/5 (4.7%)
AJCC stage
Stages IA/IB 18 (16.8%)/11 (10.3%)
Stages IIA/IIB 13 (12.1%)/13 (12.1%)
Stages IIIA/IIIB/IIIC 17(15.9%)/11 (10.3%)/19 (17.8%)
Stage IV 5 (4.7%)
Anatomical regions
GEJ_Cardia 8 (7.5%)
Fundus_Body 36 (34.3%)
Antrum 54 (50.5%)
Antrum_Body 5 (4.7%)
Pylorus 3 (2.8%)
Diffuse 1 (0.9%)
Epstein-Barr virus infection
(Continued )
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Characteristics Number
Negative 100 (93.5%)
Positive 7 (6.5%)
Microsatellite instability(MSI)
MSS 88 (82.2%)
MSI-I 4 (3.7%)
MSI-H 15 (14.0%)
H. pylori infection
Negative 41 (38.3%)
Positive 66 (61.7%)
Abbreviations: GEJ, gastroesophageal junction; H. pylori, Helicobacter pylori; pT stage, pathological assessment of the 
primary tumor; pN stage, pathological assessment of the regional lymph nodes.
Table 2: Germline SNPs in TP53, STK11, ALK, APC, MSH2, MLH1, and CDH1 genes of 107 Korean gastric cancer 
patients
Sample Chromosome Start End Ref Alter Gene Transcript ID
Amino 
acid 
change
Total 
depth
VAF(%)
(1)a
VAF 
(%)
(2)b
Clinical 
significance
YMC 54 2 29449820 29449820 G A ALK NM_004304.4 p.T1012M 637 48.51% 60.36% Benign
YMC 7 2 29449820 29449820 G A ALK NM_004304.4 p.T1012M 208 55.77% 43.83% Benign
YMC 70 2 29449820 29449820 G A ALK NM_004304.4 p.T1012M 755 52.58% 57.85% Benign
SKW 18 2 29519923 29519923 G A ALK NM_004304.4 p.L550F 155 38.06% 55.39% VUS
YMC 13 5 112177778 112177778 A C APC NM_001127511.2 p.K2145Q 151 52.32% 33.74% Benign
YMC 24 5 112178865 112178865 G A APC NM_001127511.2 p.R2507H 1142 47.90% 49.52% VUS
SKW 38 5 112176548 112176548 G C APC NM_001127511.2 p.A1735P 628 45.86% 47.30% VUS
SKW 21 5 112173895 112173895 A C APC NM_001127511.2 p.E850D 147 55.78% 50.93% Benign
YMC 29 16 68867247 68867247 G A CDH1 NM_004360.4 p.V832M 1337 52.21% 49.75% Likely 
pathogenic
YMC 37 16 68867247 68867247 G A CDH1 NM_004360.4 p.V832M 1498 50.73% 46.41% Likely 
pathogenic
SKW 16 16 68856080 68856080 C G CDH1 NM_004360.4 p.L630V 928 43.74% 40.61% Benign
SKW 15 16 68856080 68856080 C G CDH1 NM_004360.4 p.L630V 827 49.33% 71.46% Benign
YMC 53 3 37053562 37053562 C T MLH1 NM_000249.3 p.R217C 1397 46.96% 50.40% VUS
YMC 55 3 37042521 37042521 T G MLH1 NM_000249.3 p.S95A 233 39.06% 30.52% VUS
YMC 6 3 37067240 37067240 T A MLH1 NM_000249.3 p.V384D 578 48.79% 44.85% Benign
YMC 70 3 37067240 37067240 T A MLH1 NM_000249.3 p.V384D 547 51.55% 47.99% Benign
YMC 14 3 37053562 37053562 C T MLH1 NM_000249.3 p.R217C 1409 45.71% 51.65% VUS
YMC 22 3 37067240 37067240 T A MLH1 NM_000249.3 p.V384D 862 99.54% 100% Benign
YMC 3 3 37090506 37090506 C A MLH1 NM_000249.3 p.Q701K 369 51.49% 41.29% Benign
YMC 4 3 37089022 37089022 C G MLH1 NM_000249.3 p.L582V 364 48.63% 57.47% VUS
YMC 37 3 37053562 37053562 C T MLH1 NM_000249.3 p.R217C 1315 49.20% 49.76% VUS
(Continued )
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Sample Chromosome Start End Ref Alter Gene Transcript ID
Amino 
acid 
change
Total 
depth
VAF(%)
(1)a
VAF 
(%)
(2)b
Clinical 
significance
YMC 48 3 37067240 37067240 T A MLH1 NM_000249.3 p.V384D 899 43.38% 44.61% Benign
SKW 31 3 37053562 37053562 C T MLH1 NM_000249.3 p.R217C 294 55.78% 39.71% VUS
YMC 66 2 47656972 47656972 C T MSH2 NM_000251.2 p.L390F 197 56.85% 52.78% Benign
YMC 15 2 47656972 47656972 C T MSH2 NM_000251.2 p.L390F 1281 46.68% 79.62% Benign
YMC 28 2 47630344 47630344 C A MSH2 NM_000251.2 p.P5Q 231 53.25% 86.79% VUS
YMC 5 2 47637371 47637371 A G MSH2 NM_000251.2 p.I169V 711 51.34% 45.12% Likely 
benign
YMC 48 2 47656972 47656972 C T MSH2 NM_000251.2 p.L390F 692 51.30% 53.31% Benign
SKW 41 2 47703564 47703564 G A MSH2 NM_000251.2 p.M688I 993 52.57% 50.83% VUS
SKW 40 17 7578209 7578209 G A TP53 NM_000546.5 p.H214Y 168 39.29% 59.58% VUS
a, tumor tissue; b, matched non-tumor tissue.
Abbreviation: Ref, reference allele; Alter, Altered allele; VAF, Variant allele frequency; VUS, a variant of unknown significance.
Table 3: The location-specific recurrence of somatic variants in the 43 cancer panel genes
Gene Variantsa Mutated samples
% of mutated 
samples
COSMIC counts COSMIC ID
APC p.Glu1464ValfsTer8 2 1.90% 45
COSM1432412; 
COSM19694; 
COSM41622; 
COSM41622; 
COSM41622; 
COSM5030795
ARID1A p.Asp1850ThrfsTer33 5 4.70% 27
COSM1341426; 
COSM133001; 
COSM1666860
ARID1A p.Gln1334del/dup 23 21.50% 23
COSM1341408; 
COSM298325; 
COSM1578346; 
COSM133030; 
COSM51218; 
COSM1238047
ARID1A p.Gly87del 2 1.90% (-)
BCOR p.Gln1174ThrfsTer8 3 2.80% 5 COSM1683572; 
COSM3732385
BRAF p.Pro403LeufsTer8 2 1.90% 7
COSM1448632; 
COSM5347158; 
COSM5347157
CCND1 p.Glu280del 7 6.50% 3 COSM931394
CDH1 p.Leu15del 5 4.70% (-)
CR1 p.Arg2194Ter 10 9.30% 20 COSM301989
ERBB2 p.Arg678Gln 4 3.70% 23 COSM978678; 
COSM436498
(Continued )
Oncotarget69893www.impactjournals.com/oncotarget
Gene Variantsa Mutated samples
% of mutated 
samples
COSMIC counts COSMIC ID
ERBB2 p.Ser310Phe 2 1.90% 51 COSM48358; 
COSM1666868
ERBB2 p.Val842Ile 2 1.90% 26 COSM14065; 
COSM1666633
ERBB3 p.Val104Met 2 1.90% 21 COSM20710
FBXW7 p.Arg385His 3 2.80% 41 COSM117308
HLA-B p.Glu69Val 2 1.90% 3 COSM4598273
KRAS p.Gly13Asp 5 4.70% 5039 COSM532
LARP4B p.Thr163HisfsTer47 2 1.90% 27 COSM1638669; 
COSM4968611
MVK p.Ala141ArgfsTer18 2 1.90% 17 COSM1241457
PIK3CA p.His1047Arg 4 3.70% 2115 COSM775
PGM5 p.Ile98Val 3 2.80% 47 COSM1109610
RHOA p. Arg5Gln/Trp 3 2.80% 23
COSM446704; 
COSM190569; 
COSM4770224; 
COSM4770223
RHOA p.Thr37Ala/Ile 2 1.90% 3 COSM5064959; 
COSM1223700
RHOA p.Tyr42Cys 2 1.90% 22 COSM2849892; 
COSM4770225
TP53 p.Arg248Trp 2 1.90% 56 COSM144150
TP53 p.Arg342Ter 2 1.90% 151 COSM11073
TP53 p.Cys275Tyr 2 1.90% 62 COSM10893
TP53 p.Val173Leu 2 1.90% 65 COSM43559
ZBTB20 p.Pro619LeufsTer43 5 4.70% 26 COSM267785
aRecurrent mutations observed in at least two samples.
exclusive. Genetic alterations of PTEN (n=4), PIK3CA 
(n=11), KRAS (n=11), BRAF (n=3) and MTOR (n=6) were 
detected in 25.2% of GC cases (n=27). Ten cases (9.4%) 
harbored mutated PIK3CA and KRAS G13D co-existed in 
4 cases (Figure 2).
Molecular subtype classification and clinical 
phenotype
We classified molecular subtypes using genomic 
data according to subtypes derived by TCGA and 
correlated clinical covariates of 107 GC patients with 
those molecular subtypes (Table 4). The EBV subtype 
(6.5% of GC) was significantly enriched in EBV burden 
and characterized as uncommon histological subtype 
(Table 5). In the EBV subtype, no samples with a TP53 
mutation were detected, but mutations of ARID1A (4 
cases, 57.1%), CDH1 (3 cases, 42.9%), PIK3CA (2 cases, 
28.6%) and RHOA (2 cases, 28.6%) were present with a 
relatively high frequency. Genetic alterations of the JAK2 
and PDCD1LG2 genes were not detected in the EBV 
subgroup. Only one case harbored the mutant CD274 
(Figure 1 & Table 4).
The MSI subtype (17.8% of GC) showed instability 
in one more locus in the MSI assay. The MSI subtype 
presented with an elevated mutation rate (6.6 per case) 
and was characterized by alterations of genes involved in 
mismatch repair. Almost all cases with mutations in MLH1 
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Figure 1: Summary of somatic mutations in 107 gastric cancer samples according to molecular subtype.
Figure 2: Therapeutic implications of somatic genomic alterations in 107 clinical gastric cancer cases.
(n=2/2) and MSH2 (n=4/5) were included in the MSI 
subtype. Mutations of ARID1A (73.7%), BCOR (47.4%), 
BRAF (15.8%), EGFR (21.1%), ERBB2 (26.3%), ERBB3 
(26.3%), KDR (15.8%), KRAS (26.3%), LARP4B (15.8%), 
MSH2 (21.1%), MVK (21.1%), PGM5 (21.1%), PIK3CA 
(36.8%) and ZBTB20 (26.3%) were observed with statistical 
significance. Interestingly, we observed that mutations of 
ZBTB20 were limited to the MSI group (Table 4).
The CIN subtype (43.0% of GC) was also 
characterized by a relatively low-somatic mutation rate 
(1.8 per case) and a high frequency of TP53 mutations. 
In the CIN subtype, we observed amplifications of 
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Table 4: Somatic mutations in each subtype
Somatic mutations
EBV (N=7) MSI (N=19) CIN (N=46) GS (N=35)
P value
Cases (%) Cases (%) Cases (%) Cases (%)
TP53 0 0.0% 5 26.3% 26 56.5% 10 28.6% 0.003a
ACVR1B 0 0.0% 1 5.3% 1 2.2% 0 0.0% 0.534
ALK 0 0.0% 3 15.8% 2 4.3% 1 2.9% 0.232
APC 2 28.6% 1 5.3% 8 17.4% 1 2.9% 0.050
ARID1A 4 57.1% 14 73.7% 12 26.1% 9 25.7% 0.000a
BCOR 1 14.3% 9 47.4% 2 4.3% 0 0.0% 0.016a
BRAF 0 0.0% 3 15.8% 0 0.0% 0 0.0% 0.003a
CBWD1 0 0.0% 0 0.0% 1 2.2% 1 2.9% 1.000
CCND1 0 0.0% 3 15.8% 2 4.3% 2 5.7% 0.323
CD274 1 14.3% 0 0.0% 0 0.0% 0 0.0% 0.065
CDH1 3 42.9% 1 5.3% 3 6.5% 4 11.4% 0.052
CIC 0 0.0% 5 26.3% 3 6.5% 2 5.7% 0.082
CR1 0 0.0% 5 26.3% 2 4.3% 8 22.9% 0.220
CTNNB1 1 14.3% 2 10.5% 0 0.0% 2 5.7% 0.054
EGFR 0 0.0% 4 21.1% 0 0.0% 1 2.9% 0.005a
ERBB2 0 0.0% 5 26.3% 2 4.3% 1 2.9% 0.028a
ERBB3 0 0.0% 5 26.3% 2 4.3% 2 5.7% 0.049a
FBXW7 0 0.0% 3 15.8% 3 6.5% 1 2.9% 0.301
FGFR2 0 0.0% 2 10.5% 0 0.0% 0 0.0% 0.057
HLA-B 0 0.0% 3 15.8% 2 4.3% 0 0.0% 0.088
IRF2 0 0.0% 2 10.5% 1 2.2% 1 2.9% 0.429
JAK2 0 0.0% 1 5.3% 1 2.2% 0 0.0% 0.534
KDR 0 0.0% 3 15.8% 1 2.2% 0 0.0% 0.046a
KRAS 0 0.0% 5 26.3% 1 2.2% 0 0.0% 0.002a
LARP4B 0 0.0% 3 15.8% 1 2.2% 0 0.0% 0.046a
MDM2 0 0.0% 1 5.3% 0 0.0% 0 0.0% 0.243
MEDAG 0 0.0% 2 10.5% 0 0.0% 0 0.0% 0.057
MLH1 0 0.0% 2 10.5% 0 0.0% 0 0.0% 0.057
MSH2 0 0.0% 4 21.1% 1 2.2% 0 0.0% 0.009a
MTOR 0 0.0% 3 15.8% 3 6.5% 0 0.0% 0.111
MVK 0 0.0% 4 21.1% 0 0.0% 0 0.0% 0.002a
MYC 1 14.3% 0 0.0% 0 0.0% 0 0.0% 0.065
PGM5 1 14.3% 4 21.1% 0 0.0% 0 0.0% 0.001a
PIK3CA 2 28.6% 7 36.8% 1 2.2% 0 0.0% 0.000a
PTEN 0 0.0% 2 10.5% 0 0.0% 1 2.9% 0.096
RHOA 2 28.6% 1 5.3% 2 4.3% 4 11.4% 0.139
SMAD4 0 0.0% 1 5.3% 1 2.2% 0 0.0% 0.534
STK11 0 0.0% 1 5.3% 1 2.2% 0 0.0% 0.534
ZBTB20 0 0.0% 5 26.3% 0 0.0% 0 0.0% 0.000a
Mutation rate 2.6 6.6 1.8 1.5
ap value less than 0.05.
Abbreviations: CIN, chromosomal instability, EBV, Epstein-Barr virus; GS, genomically stable; MSI, microsatellite 
instability. Fisher`s exact test was performed to evaluate differences in the respective proportions of somatic mutations 
between subgroups.
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Table 5: Patient characteristics according to molecular subtype
EBV (n=7) MSI (n=19) CIN (n=46) GS (n=35)
P value
Cases (%) Cases (%) Cases (%) Cases (%)
Age
≤50 0 0.0% 1 5.3% 3 6.5% 6 17.1% 0.580
51 ~60 2 28.6% 1 5.3% 9 19.6% 6 17.1%
61 ~70 1 14.3% 3 15.8% 13 28.3% 8 22.9%
71 ~ 80 3 42.9% 12 63.2% 16 34.8% 13 37.1%
>80 1 14.3% 2 10.5% 5 10.9% 2 5.7%
Sex
Female 1 14.3% 8 42.1% 16 34.8% 11 31.4% 0.660
Male 6 85.7% 11 57.9% 30 65.2% 24 68.6%
Lauren Class
Diffuse 3 42.9% 2 10.5% 9 19.6% 14 40.0% 0.069
Intestinal 2 28.6% 15 78.9% 26 56.5% 15 42.9%
Mixed 2 28.6% 2 10.5% 11 23.9% 6 17.1%
WHO Class
Tubular 2 28.6% 17 89.5% 32 69.6% 18 51.4% 0.000
Mucinous 0 0.0% 0 0.0% 2 4.3% 1 2.9%
Poorly cohesive 0 0.0% 0 0.0% 5 10.9% 9 25.7%
Mixed 1 14.3% 1 5.3% 7 15.2% 7 20.0%
Uncommon 4 57.1% 1 5.3% 0 0.0% 0 0.0%
pT stages
T1a/ T1b 2 28.6% 2 10.5% 10 21.7% 10 28.6% 0.778
T2 1 14.3% 3 15.8% 4 8.7% 3 8.6%
T3 1 14.3% 9 47.4% 17 37.0% 11 31.4%
T4a/ T4b 3 42.9% 5 26.3% 15 32.6% 11 31.4%
p N stages
N0 3 42.9% 10 52.6% 16 34.8% 11 31.4% 0.802
N1 1 14.3% 3 15.8% 7 15.2% 5 14.3%
N2 1 14.3% 4 21.1% 9 19.6% 6 17.1%
N3 2 28.6% 2 10.5% 14 30.4% 13 37.1%
M stages
M0 6 85.7% 19 100.0% 43 93.5% 34 97.1% 0.351
M1 1 14.3% 0 0.0% 3 6.5% 1 2.9%
AJCC Stages
Stages IA/IB 3 42.9% 4 21.1% 11 23.9% 11 31.4% 0.605
Stages IIA/IIB 1 14.3% 9 47.4% 13 28.3% 3 8.6%
(Continued )
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EBV (n=7) MSI (n=19) CIN (n=46) GS (n=35)
P value
Cases (%) Cases (%) Cases (%) Cases (%)
Stages IIIA/IIIB/IIIC 2 28.6% 6 31.6% 19 41.3% 20 57.1%
Stage IV 1 14.3% 0 0.0% 3 6.5% 1 2.9%
Anatomical regions
Antrum 1 14.3% 15 78.9% 25 54.3% 13 37.1% 0.004
Antrum_Body 1 14.3% 0 0.0% 2 4.3% 2 5.7%
Fundus_Body 4 57.1% 4 21.1% 10 21.7% 18 51.4%
GEJ_Cardia 1 14.3% 0 0.0% 7 15.2% 0 0.0%
Diffuse 0 0.0% 0 0.0% 0 0.0% 1 2.9%
Pylorus 0 0.0% 0 0.0% 2 4.3% 1 2.9%
Lymphatic invasion
Positive 4 57.1% 17 89.5% 34 73.9% 21 60.0% 0.125
Negative 3 42.9% 2 10.5% 12 26.1% 13 37.1%
Missing 0 0.0% 0 0.0% 0 0.0% 1 2.9%
Venous invasion
Positive 2 28.6% 1 5.3% 7 15.2% 5 14.3% 0.416
Negative 5 71.4% 18 94.7% 39 84.8% 29 82.9%
Missing 0 0.0% 0 0.0% 0 0.0% 1 2.9%
Perineural invasion
Positive 4 57.1% 6 31.6% 25 54.3% 17 48.6% 0.391
Negative 3 42.9% 13 68.4% 21 45.7% 17 48.6%
Missing 0 0.0% 0 0.0% 0 0.0% 1 2.9%
H. pylori infection
Negative 3 42.9% 8 42.1% 21 45.7% 9 25.7% 0.290
Positive 4 57.1% 11 57.9% 25 54.3% 26 74.3%
Abbreviations: CIN, chromosomal instability, EBV, Epstein-Barr virus; GS, genomically stable; gastric cancer, GC; GEJ, 
gastroesophageal junction; H. pylori, Helicobacter pylori; MSI, microsatellite instability; Mixed, mixed type with tubular 
and poorly cohesive; pT stage, pathological assessment of the primary tumor; pN stage, pathological assessment of the 
regional lymph nodes; Uncommon, uncommon histologic variants.
CCND1, CCNE1, ERBB2, FGFR2, KRAS, MYC, PIK3CA 
and JAK2, and a deletion of PTEN among the 43 genes 
included in the Next-Generation Sequencing (NGS) panel. 
Ten cases (21.7% in the CIN subtype) harbored CNVs 
of genes belonging to the RTK/RAS/MAPK and PI3K/
PTEN/AKT pathways (Figure 2). CNV detection using a 
targeted NGS panel of 43 genes represented 30.4 % of the 
CIN subtype (n=14/46) (Figure 1).
The GS subtype (32.7 % of GC) was characterized 
by a lack of EBV infection, MSI and somatic CNAs. The 
GS subtype showed the lowest mutation rate (1.5 per case) 
(Table 4).
Prognosis analysis in 107 gastric cancer patients
Among the 107 GC patients, the date of last follow-
up (months), loco-regional recurrence, distant metastasis, 
and cause of death were obtained from 72 patients. The 
median follow up period was 459.5 days, and there 
were 19 (26.4%) and 12 (16.7%) cases of gastric cancer 
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relapse and gastric cancer-related death, respectively. 
We conducted a survival analysis but did not observe a 
substantial difference in overall survival (p= 0.898) or 
relapse-free survival (RFS, p=0.548) among the four GC 
subtypes (Figure 3 (a) & (b)). The classification based on 
AJCC stages showed significant differences in overall 
survival (p= 0.001) or RFS (p <0.001) (Figures 3 (c) & 
(d)). Multivariate analysis showed mutant MTOR gene 
(hazard ratio [HR]:9.26, p= 0.002, 95% CI: 2.22 – 38.58), 
AJCC stages III (HR: 1.9, p= 0.013, 95% CI: 1.14 - 3.16), 
AJCC stages IV (HR: 2.15, p= 0.000, 95% CI: 1.40 - 3.30) 
and mutant CCND1 gene (HR: 5.71, p= 0.028, 95% CI: 
1.21 – 27.0) were associated with the relapse of GC. 
DISCUSSION
We analyzed germline mutations with paired 
non-tumor and GC tissue samples in 107 Korean 
patients. Two cases harbored a likely pathogenic variant 
(NM_004360.4: c. 2494 G>A, p.V832M) in the CDH1 
gene. A V832M mutation has been identified in a 
hereditary diffuse gastric cancer (HDGC) in a Japanese 
family. The probands were diagnosed at the age of 56 
[21]. This mutation were functionally characterized as 
a pathogenic mutation [22] and it was also detected in 
familial lobular breast cancer patients with the wild 
type BRCA1/2 gene [23]. Two cases with V832M were 
Figure 3: Kaplan-Meier (a) relapse-free survival (RFS) and (b) gastric cancer-specific survival (GCSS) curves were stratified by molecular 
subtypes of gastric cancer (EBV, MSI, CIN, and GS). Kaplan-Meier (c) RFS and (d) GCSS curves were analyzed by AJCC stage.
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diagnosed at age 66 and 75, in this study, respectively. 
Both cases were advanced GC in stage IIB at diagnosis 
and the family history of GC was not known.
According to the results of somatic variants, the 
Q1334del/dup (n=23/52) in ARID1A and L15del (n=6/13) 
in CDH1 were detected at a frequency of 5~33% of altered 
alleles in tumor tissue (Table 3 & Supplementary 2). 
The in-frame indel (Q1334del/dup), which increases the 
amount of the ARID1A protein in the nucleus and restores 
its tumor suppressor functions, has also been reported in 
GC samples [24]. This single nucleotide polymorphism 
(SNP) were also occasionally reported in COSMIC 
database (COSMIC v78) and pancreatic cancers [25]. A 
three-nucleotide deletion c.44_46del TGC (L15del) in 
exon 1 of CDH1, which is in the signal peptide region 
of the E-cadherin protein, was also identified in Chinese 
GC patients, whereas it was not detected in 240 controls 
[26] and endometrial carcinomas [27]. RHOA belongs 
to the Rho family, which functions in the regulation of 
the actin cytoskeleton, and functional evidence indicates 
that mutant RHOA works in a gain-of-function manner 
in this gene [28]. An RHOA mutation was observed 
in 8.4% of GC cases (n=9/107), with mutations in the 
Arg5, Gly17, Thr37, Tyr42 and Glu64 residues (Table 3 
& Supplementary 2). Among these mutations, the Arg5, 
Gly17, and Tyr42 residues are recurrently detected in GC 
[28, 29].
EBV-infected GC constitutes 5-10% of all GC cases 
[9, 10] and the Cancer Genome Atlas project demonstrated 
that EBV-infected GC is one of four molecular subtypes 
[28]. We also demonstrated that EBV-infected GC 
grouped as a molecular subtype. As in the EBV-subtype, 
ARID1A mutations (4 cases, 57.1%) were prevalent, and 
no samples with a TP53 were detected. The frequency of 
ARID1A and TP53 mutations were similar to the TCGA 
data [28]. Inhibitors of the PI3K/AKT/mTOR pathway, 
JAK2 pathway and PD-1/PD-L1, PD-L2 pathway are 
considered as potentially applicable targeted therapies in 
EBV-infected GC [4, 30]. However, only 28.6 % of EBV-
infected GC harbored PIK3CA mutations (n=2/7), and 
drug related amplifications of JAK2, CD274, PDCD1LG2 
and ERBB2 were not detected in the EBV subtype (Figure 
2). To provide applicable therapeutic options, the genetic 
alterations of PIK3CA AK2, CD274, PDCD1LG2 and 
ERBB2 should be further validated with large-scale EBV-
infected GC.
We observed that the MSI subtype was associated 
with hyper-mutations in genes and was characterized 
by a more favorable prognosis than other molecular 
subtypes. Both the TCGA and ACRG classifications 
also characterized the MSI subtype by the high 
mutation frequency and best prognosis [6, 28]. For 
intestinal type GC, patients with a good prognosis were 
characterized by a high mutation rate and microsatellite 
instability. Further, mutations of PIK3CA (29.4%) and 
KRAS (26.5%) were represented in good prognosis 
subgroup [31]. In our study, mutations of KRAS (26.3%) 
and PIK3CA (36.8%) were present with statistical 
significance in the MSI subtype, and KRAS G13D (4 
cases) and PIK3CA H1047R mutations (3 cases) were 
frequently observed (Table 2). In addition, PIK3CA 
H1047R mutations were also frequently detected in 
the MSI subtype in a previous study [6]. The genetic 
alteration of ZBTB20 (P619fs*43, n=5) was limited to 
the MSI group. This SNP (P619fs*43; rs758277701; 
COSM267785) also was limited to the MSI group and 
similar trend was observed (20% of MSI) in TCGA data 
[28]. The clinical significance of this variation should be 
evaluated through further studies.
The distribution of four GC subgroups based on 
the TCGA [28] and our data were similar (EBV, 8.8% vs. 
6.5%; MSI, 21.7% vs. 17.8%; GS, 19.7% vs. 32.7 %; CIN, 
49.8 % vs. 43.0 %). Furthermore, the proportion of EBV 
(6.4% vs. 6.5%), MSI (9.2% vs. 17.8%) and CIN subtype 
(51 % vs. 43.0 %) in Korean GC were also similar to our 
data. [32, 33].
Genetic alterations of the RTK/RAS/MAPK and 
PI3K/AKT/mTOR pathways were detected in 34.6% of 
GC cases (n=37) (Figure 2). Thirteen samples (12.2% of 
GC) harbored ERBB2 alterations, 8 contained somatic 
base substitutions and 5 harbored amplifications, with 
these events being mutually exclusive. S310F (two 
cases) and V842I substitutions (two cases) in ERBB2 
were recurrently detected in this study and have been 
functionally characterized as activating and sensitive 
to lapatinib in ERBB2-negative breast cancers. The 
functions of ERBB2 R678Q, which was also recurrently 
detected in this study, related to anti-ERBB2 (HER2)-
targeted therapy has not been tested [34]. Ten cases 
(9.4%) harbored mutated PIK3CA, and KRAS G13D co-
existed in 4 cases (Figure 2). Effects of the co-existence 
of genetic alterations of PIK3CA and KRAS on response 
to therapy are yet to be evaluated [4]. Dual PI3K and 
STAT3 blockade using NVP-BKM120 and AG490 
(STAT3 inhibitor) showed a synergistic effect in GC 
cells harboring mutated KRAS by inducing apoptosis 
[35].
These biomarkers may facilitate enrollment of GC 
patients into clinical trials evaluating targeted therapies 
and provide the basis for developing solid therapeutic 
approaches in Korean GC patients [36–38].
Molecular classification based on four GC subtypes 
showed no significant survival differences in overall 
survival (p= 0.898) or RFS (p=0.548) in this dataset. 
And, ACRG classification-based subtypes also showed 
no significant association with survival in Korean GC 
[33]. Therefore, we thought that predicting prognosis for 
Korea GC patients might be performed more simply and 
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effectively using AJCC stage [39] rather than molecular 
classification.
We classified molecular subtypes of gastric cancer 
according to the TCGA system using a targeted NGS 
panel of 43 genes, EBV, MSI, H. pylori and SNP array. 
The 43 gene cancer panel consisted of significantly 
mutated genes from the TCGA and ACRG cohort [6, 
28, 40], genes associated with new targeted therapy of 
GC (EGFR, ERBB2, FGFR2, and KDR) and hereditary 
cancer syndromes (CDH1, MSH2, MLH1, STK11, and 
TP53) [12]. We demonstrated 1) the distribution of 
GC subtypes according to TCGA molecular group, 2) 
heritable genetic alterations, 3) environmental factors 
(EBV and H. pylori), 4) somatic genetic aberrant profiles 
including driver mutations and drug-targeted genetic 
alterations, and 5) histopathological features in Korean 
GC patients.
MATERIALS AND METHODS
Subject selection
We obtained a total of 107 gastric tumors and 
matched non-tumor tissue samples from Yonsei University 
Wonju Medical Center Biobank (n=138, 69 paired 
samples) and Samkwang Medical Laboratory Biobank 
(n= 76, 38 paired samples). Tumor samples were obtained 
from patients who had not received prior chemotherapy 
or radiotherapy. The gastric cancer tissues consisted of 
69 fresh-frozen (FF) paired tumor and non-tumor tissue 
samples and 38 formalin-fixed paraffin-embedded (FFPE) 
paired tumor and non-tumor tissue samples. Clinical data, 
including age, sex, clinical follow-up data, and pathologic 
reports, were provided from the tissue source institutions. 
The histologic classification of gastric carcinoma has 
previously been based on Lauren’s criteria [2] and the 
2010 WHO classification system [3]. Tumor TNM stage 
assignment was evaluated for consistency with the 7th 
Edition of the TNM classification by the American 
Joint Committee on Cancer (AJCC) [39]. Pathologic 
findings were reviewed by experienced gastrointestinal 
pathologists (S.N.K. and M.C.). The study was approved 
by the Institutional Review Boards of Samkwang Medical 
Laboratories and Yonsei University Wonju College of 
Medicine.
DNA preparation
DNA was extracted from FFPE tumor and 
adjacent non-tumor gastric tissues using a QIAamp DNA 
extraction kit (Qiagen, Hilden, Germany) according 
to the manufacturer’s protocol. H&E-stained sections 
from FFPE blocks were reviewed by a board-certified 
pathologist, and representative sections with tumor content 
or benign tissue were identified. A G-DEX genomic DNA 
extraction kit (Intron Biotechnology, Korea) was used for 
FF tumor and matched non-tumor FF tissues according to 
the manufacturer’s protocol. The quality and concentration 
of genomic DNA (gDNA) was evaluated by Nanodrop 
(ND-1000; Thermo Scientific, DE, USA) and the Agilent 
2200 Tape Station system (Agilent Technologies, CA, 
USA) with Genomic DNA Screen Tape according to 
the manufacturer’s instructions. The DNA Integrity 
Number (DIN) for determining the integrity of gDNA 
was calculated from the electrophoretic trace on the 2200 
Tape Station system according to the manufacturer’s 
instructions. The average value (range) of total DNA 
concentration in FFPE tissue and FF tissue was 322.7 
(12.6 ~ 322.9) ng/uL and 952.8 (76.0 ~ 3756.0) ng/uL, 
respectively. The average value (range) of DIN in FFPE 
tissue and FF tissue was 2.9 (1.5 ~ 6.4) and 5.6 (1.4 ~ 8.4), 
respectively.
Detection of EBV and H. pylori infection
EBV infection was detected using the Real-Q EBV 
quantification kit (Biosewoom, Seoul, Korea) and CFX96 
real-time PCR system (Bio-Rad, USA) following the 
manufacturer’s recommendations.
H. pylori infection was detected using Giemsa stain 
(n=93) or PCR amplification and sequencing (n=14). 
Primers for PCR and sequencing were derived from 
a known sequence of the 23S rRNA gene (GenBank 
Accession No. U27270), as previously described (sense, 
5'-CGT AAC TAT AACGGT CCT AAG-3', positions 2365 
to 2385; antisense, 5'-TTA GCT AAC AGA AAC ATC 
AAG-3', positions 2635 to 2653) [41].
Configuration of a gastric cancer-related target 
gene panel for Korean gastric cancer patients
The cancer panel consisted of genes based on the 
Mutation Analysis (MutSig 2CV v3.1) results of the 
Cancer Genome Atlas (TCGA) project (http://gdac.
broadinstitute.org/runs/analyses_latest/reports/cancer/
STAD-TP/index.html, accessed at 2015.03.30) [28, 40] 
and significantly mutated genes in the Asian Cancer 
Research Group (ACRG) cohort and SMC-2 cohort in 
primary gastric cancer tissues [6]. Genes associated with 
new targeted therapy of GC (EGFR, ERBB2, FGFR2, 
and VEGFR2 (KDR)) and hereditary cancer syndromes 
(CDH1, MSH2, MLH1, STK11, and TP53) were also 
included in the cancer panel [12].
The entire length of the ROI of the NGS panel of 
43 genes was 124,132 bp. To validate the performance of 
the NGS panel of 43 genes, NA12878 reference materials 
were used 7 times in 3 batches. The panel average 
coverage is 1,710× with 97% of targeted bases covered 
>20×. We downloaded the VCF file for NA12878 (https://
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www.ncbi.nlm.nih.gov/variation/tools/get-rm/) and then 
compared it to 7 variant call sets of our control reference 
materials (NA12878). The sensitivity and specificity of 
the 43 gene cancer panel were 96.4 % (95% CI: 0.941 – 
0.979) and 100%, respectively.
Targeted sequencing and data analysis
DNA fragments of matched tumor and non-tumor 
tissues were enriched by solution-based hybridization 
capture, followed by sequencing with the Illumina 
Hiseq2500 platform (Illumina, San Diego, CA, USA) 
with the 2 × 125 bp paired-end read module. gDNA was 
sheared using an Adaptive Focused Acoustics (AFA) 
™ with the Covaris Focused-ultrasonicator (Covaris, 
Inc., Woburn, MA, USA). The quality and quantity of 
sheared DNA were assessed using the Agilent 2200 Tape 
Station system with Agilent D1000 ScreenTape (Agilent 
Technologies, USA) according to the manufacturer’s 
instructions. Capture probes for the coding exons 
of 43 genes (Supplementary 1)were generated by 
Celemics (Seoul, Korea). Purification and clean-up 
of samples were performed using a DynaMag™-50 
Magnet (Thermo Fisher Scientific Inc., Waltham, MA, 
USA) with Agencourt® AMPure® XP Kit (Beckman 
Coulter, Brea, CA, USA). NGS library amplification 
was performed using a KAPA Library Amplification 
Kit (Kapa Biosystems, Inc., Wilmington, MA, USA) 
according to the manufacturer’s instructions. Library 
preparation, hybridization, capture procedure, and 
sequencing on the Illumina HiSeq2500 genome analyzer 
were performed by Celemics according to the protocols 
recommended by the Celemics User Manual Ver 2.1 
(http://www.celemics.com/home/).
The generated reads were trimmed and filtered 
by Trimmomatic [42] and then mapped against the 
UCSC hg19 Genome Reference Consortium Human 
Reference 37 (GRCh37) (http://genome.ucsc.edu/) 
using the Burrows-Wheeler Aligner (BWA) [43]. Picard 
(http://broadinstitute.github.io/picard/), SAMTools 
[44], and Genome Analysis Toolkit (GATK, https://
www.broadinstitute.org/gatk/) [45] were used for post-
processing alignments, base quality score recalibration, 
and short insertion/deletion (indel) realignment. After 
variant calling, variants were added to the annotation 
using ANNOVAR (http://www.openbioinformatics.org/
annovar/)[46] and Variant Effect Predictor (VEP, http://
asia.ensembl.org/info/docs/tools/vep/index.html). We 
used Varscan 2 (http://varscan.sourceforge.net) [47] for 
the detection of somatic SNVs and indels.
All acquired candidate variations went through 
post filters recommended by the authors of these tools. 
We extracted somatic mutations with Varscan2 and 
post-filtered with downstream analysis for altered allele 
frequency in tumors > 5%, > 50 x coverage, exonic 
variants, and population frequency 0.005 less than in 
the 1000 Genome Project (http://www.1000genomes.
org), ESP6500 (http://evs.gs.washington.edu/EVS/), 
and Exome Aggregation Consortium (ExAC, http://
exac.broadinstitute.org/). We excluded somatic variants 
detected >2 times in non-tumor tissue. We identified 
germline variations post-filtered with downstream 
analysis for altered allele frequency > 30%, > 50x 
coverage, and population frequency less than 0.01 in the 
1000 Genome Project, ESP6500, and ExAC databases. 
These variants were present in both GC and matched 
non-tumor" tissue. Visual inspection of filtered calls 
was performed using Integrated Genomics Viewer 2.3 
software (IGV; Broad Institute, Cambridge, MA, USA).
CNV analysis
CNV analysis of the NGS panel of 43 genes was 
performed with dispersion and the Hidden Markov 
Model (HMM) method with normalized counts 
in NextGENe v2.4.1.2 - CNV tool (Softgenetics, 
State College, PA, USA). The dispersion value was 
automatically calculated and an HMM was used to 
merge multiple-exon calls and apply a priori probability. 
Using the coverage ratio value and the amount of noise 
in each region, the copy number state of each region in 
the sample was reported (duplication/normal/deletion) 
[48]. The NextGENe Viewer (SoftGenetics) was used 
to visualize the several large CNV calls. To validate the 
performance of this tool, we compared its results to Her2 
immunohistochemistry (IHC) results. Fifty-four cases 
performed with Her2 IHC consisted of 4 positive cases 
(score: 3+) and 39 negative cases. We compared the 
Her2 IHC results and the CNV results from NextGENe-
CNV analysis. The sensitivity and specificity of CNV 
analysis were 75.0% (95% CI: 0.194 – 0.993) and 100% 
(95% CI: 0.929 – 1.0), respectively.
The Infinium® Global Screening Array (Illumina, 
San Diego, CA, USA) was performed for 69 FF tumor 
tissues and 22 FFPE tumor tissues according to the 
manufacturer’s recommendations. The hybridized arrays 
were scanned using the HiScan system (Illumina, San 
Diego, CA, USA). CNA analysis from single nucleotide 
polymorphism (SNP) based arrays were performed using 
GISTIC 2.0. [49]. To eliminate bias from copy number 
variable regions in healthy individuals, we analyzed 
CNV in a certain range, including somatic CAN-reported 
regions in GCs (http://www.cbioportal.org/) and dosage-
sensitive regions of the genome [50].
Microsatellite instability (MSI) assay
Microsatellite status was assessed by the 
mononucleotide repeat markers BAT-25, BAT-26, NR-
21, NR-24, and NR-27 in tumor and corresponding 
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non-tumor tissues [51]. The five markers were co-
amplified in multiplex PCRs performed with Solg2X 
multiplex PCR Smart mix following the manufacturer’s 
recommendations. The amplified PCR products were 
analyzed using the ABI 3500Dx system (Applied 
Biosystems, Foster City, CA, USA) and GeneMarker 
software (SoftGenetics, PA, USA). Tumors with two 
or more of the five markers showing instability were 
judged as high-frequency MSI (MSI-H), and tumors 
showing instability in only one locus were classified as 
low-frequency MSI (MSI-L) [52].
Molecular subtype classification and statistical 
analysis
As with the TCGA classification sequence [5], 
we also divided GC into EBV, MSI and CIN serially 
according to the results of EBV, MSI and SNP arrays. The 
remainder was then classified into the GS subgroup.
Fisher`s exact and Chi-squared tests were performed 
to evaluate differences in the respective proportion of 
several factors between subgroups. Patient follow-up 
periods were calculated as time between date of surgery 
and date of last follow-up (months). Relapse-free survival 
(RFS) was assessed based on the absence of loco-regional 
recurrence, distant metastasis, and death from any cause. 
GC-specific survival (GCSS) was calculated only for 
patients who died from any GC-related cause. Kaplan-
Meier survival curves with log-rank tests were performed 
to compare RFS and GCSS according to AJCC stage and 
molecular subtype. Cox proportional hazard models were 
performed to assess the influence of prognostic factors 
on RFS. All statistical analyses were performed using 
SPSS 22.0 (SPSS, Chicago, IL, USA). Except for the 
univariate analysis, a p value less than 0.05 was regarded 
as significant.
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